Fibrinolytic therapy with urokinase
Phase 2
- Conditions
- Refractory intrathoracic infectionRefractory intrathoracic infection, urokinase, fibrinolytic therapy
- Registration Number
- JPRN-jRCTs031180292
- Lead Sponsor
- Yajima Toshiki
- Brief Summary
The intrathoracic application of urokinase for treatment of complicated pleural infections was effective in 85% of cases. There were severe adverse events in 15% of patients, which were considered to be related to the underlying comorbidity. The same patients required a surgical intervention.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
1.Patient with refractory intrathoracic infection
2. Patient with thoracic drain
3. Hospitalized patient
4. Patient with consent
Exclusion Criteria
1.Patient with active intrathoracic bleeding
2. Patients considered unfit to participate by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method